[go: up one dir, main page]

SE9003665D0 - Morphine prodrugs - Google Patents

Morphine prodrugs

Info

Publication number
SE9003665D0
SE9003665D0 SE9003665A SE9003665A SE9003665D0 SE 9003665 D0 SE9003665 D0 SE 9003665D0 SE 9003665 A SE9003665 A SE 9003665A SE 9003665 A SE9003665 A SE 9003665A SE 9003665 D0 SE9003665 D0 SE 9003665D0
Authority
SE
Sweden
Prior art keywords
pct
morphine
date
sec
prodrugs
Prior art date
Application number
SE9003665A
Other languages
English (en)
Swedish (sv)
Inventor
H Bundgaard
Original Assignee
Kabivitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabivitrum Ab filed Critical Kabivitrum Ab
Priority to SE9003665A priority Critical patent/SE9003665D0/xx
Publication of SE9003665D0 publication Critical patent/SE9003665D0/xx
Priority to IE368291A priority patent/IE913682A1/en
Priority to NZ240349A priority patent/NZ240349A/en
Priority to ZA918512A priority patent/ZA918512B/xx
Priority to IL9990591A priority patent/IL99905A/en
Priority to FI932212A priority patent/FI932212L/fi
Priority to DK91920399T priority patent/DK0557385T3/da
Priority to JP50056892A priority patent/JP3493434B2/ja
Priority to US08/050,336 priority patent/US5908846A/en
Priority to ES91920399T priority patent/ES2121793T3/es
Priority to CA002095223A priority patent/CA2095223C/en
Priority to DE69129861T priority patent/DE69129861T2/de
Priority to AU89381/91A priority patent/AU655612B2/en
Priority to EP91920399A priority patent/EP0557385B1/en
Priority to AT91920399T priority patent/ATE168560T1/de
Priority to PCT/SE1991/000760 priority patent/WO1992008459A1/en
Priority to PT99513A priority patent/PT99513B/pt
Priority to NO93931766A priority patent/NO931766L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SE9003665A 1990-11-16 1990-11-16 Morphine prodrugs SE9003665D0 (sv)

Priority Applications (18)

Application Number Priority Date Filing Date Title
SE9003665A SE9003665D0 (sv) 1990-11-16 1990-11-16 Morphine prodrugs
IE368291A IE913682A1 (en) 1990-11-16 1991-10-21 Morphine prodrugs
NZ240349A NZ240349A (en) 1990-11-16 1991-10-25 Topical compositions for transdermal delivery of morphine prodrugs
ZA918512A ZA918512B (en) 1990-11-16 1991-10-25 Morphine prodrugs
IL9990591A IL99905A (en) 1990-11-16 1991-10-30 Topical compositions for transdermal delivery of morphine prodrugs
PCT/SE1991/000760 WO1992008459A1 (en) 1990-11-16 1991-11-11 Topical compositions for transdermal delivery of produg derivatives of morphine
US08/050,336 US5908846A (en) 1990-11-16 1991-11-11 Topical compositions for transdermal delivery of prodrug derivatives of morphine
DK91920399T DK0557385T3 (da) 1990-11-16 1991-11-11 Topiske sammensætninger til transdermal afgivelse af prodrug-derivater af morfin
JP50056892A JP3493434B2 (ja) 1990-11-16 1991-11-11 モルヒネのプロドラッグ誘導体の経皮供給用の局所組成物
FI932212A FI932212L (fi) 1990-11-16 1991-11-11 Topikal kompositioner foer transdermal transmission av morfinets prodrugderivat
ES91920399T ES2121793T3 (es) 1990-11-16 1991-11-11 Composiciones de uso local para la administracion transdermica de derivados profarmacos de morfina.
CA002095223A CA2095223C (en) 1990-11-16 1991-11-11 Topical compositions for transdermal delivery of prodrug derivatives of morphine
DE69129861T DE69129861T2 (de) 1990-11-16 1991-11-11 Topische mittel zur transdermalen verabreichung von prodrugderivaten des morphins
AU89381/91A AU655612B2 (en) 1990-11-16 1991-11-11 Topical compositions for transdermal delivery of produg derivatives of morphine
EP91920399A EP0557385B1 (en) 1990-11-16 1991-11-11 Topical compositions for transdermal delivery of produg derivatives of morphine
AT91920399T ATE168560T1 (de) 1990-11-16 1991-11-11 Topische mittel zur transdermalen verabreichung von prodrugderivaten des morphins
PT99513A PT99513B (pt) 1990-11-16 1991-11-14 Processo para a preparacao de composicoes farmaceuticas contendo profarmacos de morfina para administracao topica por via transdermica
NO93931766A NO931766L (no) 1990-11-16 1993-05-14 Topiske preparater for transdermal avlevering av forloeperlegemiddelderivater av morfin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9003665A SE9003665D0 (sv) 1990-11-16 1990-11-16 Morphine prodrugs

Publications (1)

Publication Number Publication Date
SE9003665D0 true SE9003665D0 (sv) 1990-11-16

Family

ID=20380936

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9003665A SE9003665D0 (sv) 1990-11-16 1990-11-16 Morphine prodrugs

Country Status (18)

Country Link
US (1) US5908846A (xx)
EP (1) EP0557385B1 (xx)
JP (1) JP3493434B2 (xx)
AT (1) ATE168560T1 (xx)
AU (1) AU655612B2 (xx)
CA (1) CA2095223C (xx)
DE (1) DE69129861T2 (xx)
DK (1) DK0557385T3 (xx)
ES (1) ES2121793T3 (xx)
FI (1) FI932212L (xx)
IE (1) IE913682A1 (xx)
IL (1) IL99905A (xx)
NO (1) NO931766L (xx)
NZ (1) NZ240349A (xx)
PT (1) PT99513B (xx)
SE (1) SE9003665D0 (xx)
WO (1) WO1992008459A1 (xx)
ZA (1) ZA918512B (xx)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
DE4403709A1 (de) * 1994-02-07 1995-08-10 Lohmann Therapie Syst Lts Pharmazeutische Zusammensetzung zur systemischen transdermalen Verabreichung mit dem Wirkstoff Morphin-6-glucuronid
JPH07267862A (ja) * 1994-03-29 1995-10-17 Sekisui Chem Co Ltd 経皮吸収貼付剤
DE19508664C2 (de) * 1995-03-14 2001-08-23 Christian Mignat Verwendung von Morphin-3-estern, Morphin-3-ester als solche und Verfahren zu deren Herstellung
AU5108596A (en) * 1995-03-14 1996-10-02 Mundipharma Gmbh Morphine-3-esters
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
DE19602963A1 (de) * 1995-12-20 1997-07-31 Nycomed Arzneimittel Gmbh Neue Morphinderivate, Verfahren zu deren Herstellung und deren Verwendung
DE19923551A1 (de) * 1999-05-21 2000-11-30 Lohmann Therapie Syst Lts Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht
CN107213128A (zh) 1999-10-29 2017-09-29 欧罗赛铁克股份有限公司 控释氢可酮制剂
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US20020013331A1 (en) * 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
CN101653411A (zh) 2000-10-30 2010-02-24 欧罗赛铁克股份有限公司 控释氢可酮制剂
US6569449B1 (en) * 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
AUPR549901A0 (en) * 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
AU1482102A (en) * 2000-11-14 2002-05-27 Tocovite Pty Ltd Complexes of phosphate derivatives
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
BR0210179A (pt) * 2001-06-05 2004-04-27 Control Delivery Sys Inc Compostos analgésicos de liberação sustentada
CA2453823C (en) * 2001-07-27 2010-12-21 Vital Health Sciences Pty Ltd Dermal therapy using phosphate derivatives of electron transfer agents
EP1460995B1 (en) * 2001-12-13 2010-11-10 Vital Health Sciences Pty Ltd. Transdermal transport of compounds
AU2002950713A0 (en) * 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
US7084150B2 (en) * 2002-10-25 2006-08-01 Euro-Celtique S.A. Analogs and prodrugs of buprenorphine
US20040152769A1 (en) * 2002-11-09 2004-08-05 Ekwuribe Nnochiri Nkem Modified carbamate-containing prodrugs and methods of synthesizing same
BRPI0406484A (pt) * 2003-01-17 2005-12-06 Vital Health Sciences Pty Ltd Método de inibição da ocorrência de uma ou mais das seguintes condições: a proliferação de monócitos/macrófagos; ou a proliferação de células do músculo liso; ou a expressão de receptores de cd36; ou a absorção de lipoproteìna de baixa densidade - ldl oxidada, método de alìvio de sintomas de tratamento ou prevenção de aterosclerose; de diabetes; do mal de alzheimer, método de inibição da ocorrência da formação de placas no sistema vascular, método de alìvio da inflamação associada a ocorrência de uma ou de mais das seguintes condições: a proliferação de monócitos, a proliferação de células do músculo liso, a expressão de ldl oxidadas ou de receptor descontaminante, composição farmacêutica, uso de uma quantidade eficaz de um ou mais derivados ou fosfato de um ou mais agentes de transferência de elétrons conjuntamente com um veìculo ou um diluente apropriado, uso de uma quantidade eficaz de um ou mais derivados de fosfato de (alfa)-tocoferol conjuntamente com um veìculo ou um diluente apropriado e uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons selecionados do grupo que consiste em fosfato mono-tocoferila, fosfato de di-tocoferila e as misturas destes conjuntamente com um veìculo ou um diluente apropriado
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
PT1638492E (pt) * 2003-07-25 2008-03-17 Euro Celtique Sa Tratamento pré-operatório da dor pós-operatória
EP2194059A3 (en) 2004-02-06 2010-09-22 Euro-Celtique S.A. Methods for making 3-O-protected morphinones and 3-O-protected morphinone dienol carboxylates
ATE426399T1 (de) 2004-02-23 2009-04-15 Euro Celtique Sa Missbrauchsichere transdermale abgabevorrichtung fur opioide, enthaltend opioidantagonist in form von mikrokugelchen
AU2005202477B2 (en) * 2004-03-03 2005-12-15 Vital Health Sciences Pty Ltd Alkaloid formulations
CA2611831C (en) 2005-06-17 2014-09-16 Vital Health Sciences Pty Ltd. A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
US20090005348A1 (en) * 2005-12-23 2009-01-01 Vital Health Sciences Pty Ltd Compounds Having Cytokine Modulating Properties
CA2679316C (en) 2007-03-02 2016-11-29 Teika Pharmaceutical Co., Ltd. Morphine composition for transdermal absorption, morphine composition storing unit and transdermal absorption preparation using the same
US9511016B2 (en) * 2007-06-12 2016-12-06 Epicentrx, Inc. Topical composition for treating pain
US8354116B2 (en) * 2007-06-18 2013-01-15 Biochemics, Inc. Bifunctional synthetic molecules
US8784872B2 (en) 2007-11-19 2014-07-22 Comgenrx, Inc. Formulation for decreasing tobacco, alcohol, drug or food consumption
US20090130048A1 (en) * 2007-11-19 2009-05-21 Oronsky Bryan Todd Topical Composition for Treating Pain
WO2009158667A2 (en) * 2008-06-27 2009-12-30 Comgenrx, Inc. Povidone compositions for wound healing
US10849981B2 (en) 2009-07-02 2020-12-01 KemPham, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
AU2010266209B2 (en) 2009-07-02 2013-09-26 Kempharm, Inc. Phenylethanoic acid, phenylpropanoic acid and phenylpropenoic acid conjugates and prodrugs of hydrocodone, methods of making and use thereof
UA102916C2 (uk) * 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
WO2011094814A1 (en) 2010-02-05 2011-08-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
AU2011235597B2 (en) 2010-03-30 2015-07-16 Phosphagenics Limited Transdermal delivery patch
DK2557924T3 (da) 2010-04-13 2019-09-23 Relmada Therapeutics Inc Dermale farmaceutiske sammensætninger af 1-methyl-2',6'-pipecoloxylidid og fremgangsmåde til deres anvendelse
TWI590821B (zh) 2011-01-18 2017-07-11 輝瑞有限公司 固體分子分散液
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
BR112017011069A2 (pt) 2014-11-25 2018-07-10 Kempharm Inc ácido benzóico, derivados e ácido benzóico e conjugados de ácido heteroaril carboxílico de oxicodona
US10973761B2 (en) 2015-12-09 2021-04-13 Phosphagenics Limited Pharmaceutical formulation
MX392823B (es) 2016-12-21 2025-03-24 Avecho Biotechnology Ltd Proceso de fosforilaciónde un alcohol complejo

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4673679A (en) * 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
US4908389A (en) * 1986-08-27 1990-03-13 Warner-Lambert Company Penetration enhancement system
US4940586A (en) * 1987-02-26 1990-07-10 Alza Corporation Skin permeation enhancer compositions using sucrose esters
US4879297A (en) * 1987-06-01 1989-11-07 Warner-Lambert Company Fatty acids and their small chain esters as penetration enhancers in aqueous systems
US4891377A (en) * 1988-12-02 1990-01-02 Board Of Regents Acting For And On Behalf Of University Of Michigan Transdermal delivery of the narcotic analgesics etorphine and analogs
AU7547891A (en) * 1990-03-30 1991-10-30 Yasunori Morimoto Percutaneously absorbable composition of narcotic and nonnarcotic analgesics
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine

Also Published As

Publication number Publication date
US5908846A (en) 1999-06-01
PT99513A (pt) 1992-09-30
ZA918512B (en) 1992-08-26
ATE168560T1 (de) 1998-08-15
CA2095223C (en) 2002-12-17
CA2095223A1 (en) 1992-05-17
JPH06502422A (ja) 1994-03-17
NO931766D0 (no) 1993-05-14
IL99905A0 (en) 1992-08-18
JP3493434B2 (ja) 2004-02-03
FI932212A0 (fi) 1993-05-14
NZ240349A (en) 1993-07-27
AU655612B2 (en) 1995-01-05
DK0557385T3 (da) 1999-04-26
EP0557385A1 (en) 1993-09-01
IE913682A1 (en) 1992-05-20
ES2121793T3 (es) 1998-12-16
EP0557385B1 (en) 1998-07-22
FI932212A7 (fi) 1993-05-14
NO931766L (no) 1993-05-14
DE69129861T2 (de) 1999-04-01
PT99513B (pt) 1999-04-30
DE69129861D1 (de) 1998-08-27
AU8938191A (en) 1992-06-11
IL99905A (en) 1995-06-29
FI932212L (fi) 1993-05-14
WO1992008459A1 (en) 1992-05-29

Similar Documents

Publication Publication Date Title
SE9003665D0 (sv) Morphine prodrugs
MY107158A (en) 3-arylcarbonyl; -1h-indoles useful as therapeutic agents.
CY2431B1 (en) Novel phenanthridines substituted in the 6 position.
GB2270075B (en) Substituted 2-phenyl-3-methoxypropenoate fungicides
GR3015141T3 (en) Nail enamels containing glyceryl triesters.
FI954963A0 (fi) Poly-1-n-alkeeniamiineja ja näitä sisältäviä poltto- ja voiteluainekoostumuksia
MX9700886A (es) Nuevas oxazolidinonas sustituidas.
CY2473B1 (en) New phenanthridines.
MX9203319A (es) Metodo para la preparacion de cristales de alfa-2 interferona.
BR0009524A (pt) Uso de um composto, e, composição farmacêutica ou veterinaria
TR199900951T2 (xx) G���s kanserinin engellenmesi i�in y�ntemler.
MX9709398A (es) N-aril-1,2,4-triazolin-5-onas.
DE69104448D1 (de) Faserbehandlungsmittelzusammensetzung.
IT1243193B (it) Composizioni farmaceutiche orali a base di melatonina
DK0662837T3 (da) Anvendelse af IL-10 til forhindring af insulinafhængig diabetes mellitus
DK0550580T3 (da) Inaktivator for uracilreduktase
BR9305261A (pt) Composição implantável com liberação controlada
DK0458589T3 (da) Behandling af okulær hypertension med en okulær synergistisk kombination
DE59000613D1 (de) Pflaster zur transdermalen anwendung.
ES2044100T3 (es) Ciertas combinaciones de antagonistas del "paf" y antihistaminicos y metodos.
ES2056876T3 (es) Compuestos piperidinilicos 1,4-disustituidos.
DK0669826T3 (da) (-)-Metrifonatholdigt lægemiddel
ES2097816T5 (es) Producto y su uso para el tratamiento de estados catabolicos que comprende ifg-1 autentico y cantidades hipocaloricas de nutrientes.
MX9701606A (es) Terapia de combinacion para evitar la perdida osea-progesterona y agonistas de estrogeno.
ZA92510B (en) Vaccine composition against influenza,with synergic effects,containing influenza virus core as an additive